Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
Open Access
- 2 November 2022
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 93 (1), 103-108
- https://doi.org/10.1002/ana.26534
Abstract
Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS-CoV-2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS-CoV-2 IgG anti-RBD titers after vaccination (comparable to B-cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B-cell depleted patients with MS. ANN NEUROL 2022Funding Information
- ZonMw (10,430,072,010,007)
- Health Research
This publication has 19 references indexed in Scilit:
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisNeurology, 2021
- SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS CohortJAMA Neurology, 2021
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responsesCell Reports Medicine, 2021
- Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donorsClinical & Translational Immunology, 2021
- Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIOBritish Journal of Clinical Pharmacology, 2020
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisNeurology, 2020
- Personalized extended interval dosing of natalizumab in MSNeurology, 2020
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2017
- Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?Clinical Pharmacology & Therapeutics, 2015
- Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibodyAnalytical Biochemistry, 2011